ERBB2 and gastric cancer: The results obtained in targeting her2 in other tumors such as breast, skin, gastric cancers, together with the knowledge of a certain incidence of her2 overexpression in mCRC tumors (about 2%), has led clinical research to study the efficacy data of the anti-her2 target treatment in this category of patients.